You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九典制藥(300705.SZ)2024年度淨利潤增39.13%至5.12億元 擬10派3.1元
格隆匯 04-23 16:53

格隆匯4月23日丨九典制藥(300705.SZ)發佈2024年年度報吿,2024年度公司合併報表範圍內實現營業收入293,067.75萬元,較上年同期增長8.85%;歸屬於上市公司股東的淨利潤51,237.72萬元,較上年同期增長39.13%;歸屬於上市公司股東的扣非後淨利潤47,468.33萬元,較上年同期增長39.68%,擬向全體股東每10股派發現金紅利3.10元。

2024年,公司喜獲中國工人階級最高獎項之一的"全國五一勞動獎狀",成為湖南省唯一獲此殊榮的藥企;連續入圍"中國醫藥製造業百強""中國醫藥行業成長50強"榜單;榮登中國化藥企業排行榜第51位,較上年大幅提升19位;入選2024中國藥品研發實力三項榜單,化藥研發實力首進全國50強。此外,普道醫藥及九典宏陽六車間分別獲得"湖南省企業技術中心""湖南省智能製造標杆車間"認定,公司酮洛芬凝膠貼膏、西甲硅油原料藥2個品種也成功入選省生物醫藥產業鏈重點品種。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account